RAPAMYCINDERIVATE

European patent · EP3898637 · In force

Register entry

Publication number
EP3898637
Application number
EP19836546
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 17, 2019
Published
Oct 27, 2021
Granted
Nov 20, 2024
Protection ends at the latest
Dec 16, 2039
Next annual fee due
Dec 31, 2026
IPC classes
C07D 498/18 (2006.01)
A61K 31/436 (2006.01)
A61P 35/00 (2006.01)
A61P 37/00 (2006.01)
Priority
US 201862781242 P 18.12.2018
PCT application
PCT/IB2019/060957 17.12.2019
PCT publication
WO2020/128861 25.06.2020
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 1, 2026

    Change

    Published in Swissreg on 01.01.2026

  2. Sep 24, 2025

    Change

    Published in Swissreg on 24.09.2025

  3. Feb 20, 2025

    Change

    Published in Swissreg on 20.02.2025

  4. Feb 14, 2025

    Agent entered

    Representative
    VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 14.02.2025

  5. Nov 20, 2024

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 20.11.2024

Parties

Holder

Novartis AG

Lichtstrasse 35, 4056 Basel

Agent

VALIPAT c/o BOVARD LTD

Optingenstrasse 16, 3013 Bern

Inventor

BONAZZI, Simone

Cambridge, Massachusetts 02139, US

CONNOLLY, Michael

Cambridge, Massachusetts 02139, US

GLASS, David J.

Cambridge, Massachusetts 02139, US

MIHALIC, Manuel

4002 Basel

PATTERSON, Andrew W.

Cambridge, Massachusetts 02139, US

ROGGO, Silvio

4002 Basel

SHAVLAKADZE, Tea

Cambridge, Massachusetts 02139, US

ZUEGER, Patrik

4002 Basel

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.